CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nanjing Shangyuantang Pharmaceutical is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nanjing Shangyuantang Pharmaceutical
China

Business Summary
Nanjing Shangyuantang Pharmaceutical Joint Stock Co., Ltd. is a China-based company principally engaged in the medicines retailing business. The Company provides medicines including prescription medicines and over-the-counter drugs, medical equipment, health care products, disinfection supplies, personal care products and others. The Company also involves in the development and distribution of agilawood and agilawood related products. The Company provides its products through drug stores and Internet stores.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201312/31/2013Yes----

General Information
Outstanding Shares: 10,000,000 (As of 12/31/2013)


Copyright © 2021 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 13, 2021